Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.37) by 16.22 percent. This is a 34.37 percent decrease over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $(1.78 million) which missed the analyst consensus estimate of $4.63 million by 138.49 percent. This is a 161.06 percent decrease over sales of $2.92 million the same period last year.